INTERSTIMT SYSTEMS WITH SURESCANT MRI TECHNOLOGY

THERAPY WITHOUT LIMITS

Treat more patients with expanded MRI eligibility

FULL-BODY* MRI

1.5T 3T


MRI technicians trust the SureScan™ MRI brand for its simple, convenient, and streamlined workflow

SIMPLE

- No impedance checks required prior to MRI scans
- Scans allowed even if patients have had out-of-range impedances

CONVENIENT

- MRI mode is easy to activate or deactivate on a smart programmer without clinician or Medtronic interaction
- Digital display for clear confirmation of MRI mode



The most common adverse events associated with sacral neuromodulation include pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.

*Under certain conditions. See approved labeling for details.
Patients with InterStim™ SureScan™ MRI Leads only.





See the device manual for detailed information regarding the instructions for use, implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative or consult the Medtronic website at **medtronic.com**

Indications for Use:

Sacral Neuromodulation delivered by the InterStim system for Urinary Control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.

The following Warning applies only to Sacral Neuromodulation for Urinary Control:

 $\textbf{Warning:} \ This \ therapy \ is \ not \ intended \ for \ patients \ with \ mechanical \ obstruction \ such as \ benign \ prostatic \ hypertrophy, \ cancer, \ or \ ure thral \ stricture.$

Sacral Neuromodulation delivered by the InterStim $^{\mathbb{M}}$ system for Bowel Control is indicated for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments.

Contraindications for Urinary Control and for Bowel Control: Diathermy. Patients who have not demonstrated an appropriate response to test stimulation or are unable to operate the neurostimulator.

Warnings/Precautions/Adverse Events:

For Urinary Control: Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 16; or for patients with neurological disease origins.

For Bowel Control: Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 18; or for patients with progressive, systemic neurological diseases.

For Urinary Control and for Bowel Control: The system may be affected by or adversely affect cardiac devices, electrocautery, defibrillators, ultrasonic equipment, radiation therapy, MRI, theft detectors/screening devices. Adverse events include pain at the implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations, including jolting or shock sensations. Patients should be assessed preoperatively for the risk of increased bleeding. For full prescribing information, please call Medtronic at 1-800-328-0810 and/or consult Medtronic's website at www.medtronic.com. Product technical manual must be reviewed prior to use for detailed disclosure.

USA Rx Only. Rev 0517

Medtronic

710 Medtronic Parkway Minneapolis, MN 55432-5604 USA Tel: (763) 514-4000

medtronic.com

© 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. UC202010814a EN